All Outputs (47)

Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis (2011)
Journal Article
Hodgkinson, V. C., ELFadl, D., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. Journal of Proteomics, 74(5), 698-703. https://doi.org/10.1016/j.jprot.2011.02.014

Antibody microarrays are powerful new tools in the field of comparative proteomics. The success of the biomarker discovery pipeline relies on the quality of data generated in the discovery phase and careful selection of proteins for the verification... Read More about Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis.

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? (2010)
Journal Article
Agarwal, V., Lind, M. J., & Cawkwell, L. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), 533-542. https://doi.org/10.1016/j.ctrv.2010.11.004

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant... Read More about Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?.

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status (2010)
Journal Article
Hodgkinson, V. C., Eagle, G. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2010). Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Letters, 294(1), 13-24. https://doi.org/10.1016/j.canlet.2010.01.036

This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (... Read More about Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? (2009)
Journal Article
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., Garimella, V., Lind, M. J., Drew, P. J., & Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), 1194-1207. https://doi.org/10.1593/neo.09902

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitiviti... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J.-M., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.

The proteomic analysis of resistance to anticancer therapy in human breast cancer (2006)
Thesis
Smith, L. (2006). The proteomic analysis of resistance to anticancer therapy in human breast cancer. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4212607

Resistance to anticancer therapy represents a major barrier in the successful management of human breast cancer. The identification of novel biomarkers that correlate with treatment response would increase our understanding of the resistance mechanis... Read More about The proteomic analysis of resistance to anticancer therapy in human breast cancer.